The TRAIL death receptor-4 (DR-4) has also been identified as a potential mir-25 target, with reports of mir-25 being upregulated in prostate carcinoma, gastric adenocarcinoma, cholangiocarcinoma and other human cancers [39]. This evidence concerns the gene TNFRSF10A and gastric adenocarcinoma.